Compare NWTG & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | ERNA |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.3M |
| IPO Year | 2022 | 2021 |
| Metric | NWTG | ERNA |
|---|---|---|
| Price | $0.92 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 219.0K | 32.0K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,135,000.00 | $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $1.84 |
| 52 Week High | $1.94 | $71.50 |
| Indicator | NWTG | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 30.06 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.17 | $4.72 |
| Average True Range (ATR) | 0.15 | 0.29 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 24.55 | 19.38 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.